INS and type 2 diabetes mellitus: Previous studies conducted in USA and Europe have shown that adding a DPP-4 inhibitor to insulin in patients with T2DM reduced HbA1c[9–11], but the incidence of hypoglycemia was increased in one study in which sitagliptin was used[9].